Global investments into neglected disease R&D
The G-FINDER project tracks and reports on global investments into research and development (R&D) for neglected diseases.
G-FINDER is a uniquely informative data source, providing policy-makers, donors, researchers and industry with objective, previously unavailable information on the state of investment, trends and patterns:
- in 39 neglected diseases and select viral haemorrhagic fevers (VHFs)
- across 160 product areas for these diseases including drugs, vaccines, diagnostics, microbicides and vector control products and
- in platform technologies (e.g. adjuvants, delivery technologies, diagnostic platforms)
The data includes all types of product-related R&D, including basic research, discovery and preclinical, clinical development, Phase IV and pharmacovigilance studies, and baseline epidemiological studies.
Funded by the Bill & Melinda Gates Foundation since inception, the G-FINDER project was originally hosted at The George Institute for International Health and then run by Policy Cures from 2010. Following the establishment of Policy Cures Research (PCR) as a separate organisations in 2016, the G-FINDER project is conducted by Policy Cures Research.
G-FINDER database (public search tool)
The G-FINDER Public Search Tool provides open access to G-FINDER survey data that is not protected by confidentiality agreements. The Public Search Tool is updated annually and search results can be exported into Microsoft Excel for flexible data analysis.
Policy Cures Research Reports
G-FINDER 2016 Neglected Disease Research and Development: A Pivotal Moment in Global Health
The ninth G-FINDER report was launched on 16 February 2017, in Brussels, Belgium.
- G-FINDER R&D matrix (diseases, products and technologies included in the scope of the 2016 G-FINDER report)
- G-FINDER survey methodology
- G-FINDER frequently asked questions